We are live on ! Find out more
RI

RTW Investments Portfolio holdings

AUM $10B
1-Year Est. Return 135.35%
This Fund
S&P 500
This Quarter Est. Return
+41.78%
1 Year Est. Return
+135.35%
3 Year Est. Return
+383.62%
5 Year Est. Return
+523.94%
10 Year Est. Return
+15,981.64%
AUM
$1.39B
AUM Growth
+$336M
Cap. Flow
+$96.4M
Cap. Flow %
6.95%
Top 10 Hldgs %
75.78%
Holding
46
New
8
Increased
24
Reduced
6
Closed
6

Top Buys

Rank Stock Value
1
ARWR icon
Arrowhead Research
ARWR
+$50.3M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$27.4M
3
LIVN icon
LivaNova
LIVN
+$26.4M
4
QGEN icon
Qiagen
QGEN
+$18.4M
5
ILMN icon
Illumina
ILMN
+$13M

Top Sells

Rank Stock Value
1
AVXS
AveXis, Inc. Common Stock
AVXS
+$29.2M
2
GBT
Global Blood Therapeutics, Inc.
GBT
+$22.1M
3
EW icon
Edwards Lifesciences
EW
+$20.3M
4
ARMO
ARMO BioSciences, Inc. Common Stock
ARMO
+$14M
5
BMY icon
Bristol-Myers Squibb
BMY
+$10.4M

Sector Composition

Rank Sector Weight
1 Healthcare 94.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RCKT icon
1
Rocket Pharmaceuticals
RCKT
$348M
$289M 20.88%
14,969,744
– –
RGNX icon
2
Regenxbio
RGNX
$623M
$149M 10.76%
2,079,555
+201,788
+11% +$9.64M
PTCT icon
3
PTC Therapeutics
PTCT
$6.37B
$137M 9.91%
4,073,690
-64,270
-2% -$2M
SRPT icon
4
Sarepta Therapeutics
SRPT
$1.66B
$129M 9.33%
978,551
+290,280
+42% +$27.4M
ARWR icon
5
Arrowhead Research
ARWR
$12.1B
$113M 8.14%
8,299,542
+5,382,981
+185% +$50.3M
DRNA
6
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$61.8M 4.46%
5,044,813
+15,351
+0.3% +$193K
BMY icon
7
Bristol-Myers Squibb
BMY
$127B
$50M 3.61%
903,672
-192,714
-18% -$10.4M
LIVN icon
8
LivaNova
LIVN
$4.3B
$43M 3.1%
431,000
+291,000
+208% +$26.4M
LJPC
9
DELISTED
La Jolla Pharmaceutical Company
LJPC
$39.3M 2.83%
1,345,881
+223,341
+20% +$6.89M
ACHN
10
DELISTED
Achillion Pharmaceuticals
ACHN
$38.3M 2.76%
13,541,997
+45,095
+0.3% +$154K
ABUS icon
11
Arbutus Biopharma
ABUS
$865M
$37.7M 2.72%
5,165,499
+13,884
+0.3% +$82.6K
ALNY icon
12
Alnylam Pharmaceuticals
ALNY
$36.3B
$34.7M 2.5%
352,200
+105,971
+43% +$10.5M
MASI
13
DELISTED
Masimo
MASI
$24.4M 1.76%
249,543
+17,543
+8% +$1.67M
SLDB icon
14
Solid Biosciences
SLDB
$771M
$22.8M 1.64%
45,051
– –
VCEL icon
15
Vericel Corp
VCEL
$2.3B
$21.5M 1.55%
2,217,916
+150,000
+7% +$1.87M
AGEN
16
Agenus
AGEN
$249M
$21.3M 1.53%
477,679
+3,153
+0.7% +$213K
QGEN icon
17
Qiagen
QGEN
$8.53B
$19.1M 1.38%
+499,239
New +$18.4M
QURE icon
18
uniQure
QURE
$2.68B
$15.5M 1.12%
409,370
+2,703
+0.7% +$86.6K
CORI
19
DELISTED
Corium International, Inc.
CORI
$15.4M 1.11%
1,923,217
+12,695
+0.7% +$120K
ILMN icon
20
Illumina
ILMN
$29.4B
$13.9M 1%
+51,048
New +$13M
MYOK
21
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$13M 0.94%
261,395
+1,725
+0.7% +$83.5K
VRAY
22
DELISTED
ViewRay, Inc.
VRAY
$10.2M 0.74%
1,474,156
+115,445
+8% +$838K
PTE
23
DELISTED
PolarityTE, Inc. Common Stock
PTE
$10M 0.72%
+17,067
New +$10.1M
CDNA icon
24
CareDx
CDNA
$1.92B
$9.36M 0.67%
764,532
+203,932
+36% +$2.34M
APYX icon
25
Apyx Medical
APYX
$165M
$9.06M 0.65%
2,082,137
+150,189
+8% +$554K
1
2

Similar funds

MG
Mather Group Chicago, Illinois $10B AUM 15.14% 1-Year Est. Return
LWCFA
Loring Wolcott & Coolidge Fiduciary Advisors Boston, Massachusetts $9.98B AUM 4.97% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
OAM
OP Asset Management Helsinki $9.95B AUM 30.22% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return
IIM
INTECH Investment Management West Palm Beach, Florida $10.2B AUM 28.14% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

RTW Investments's Q2 2018 Portfolio in Review

As of Q2 2018, RTW Investments held 46 positions worth $1.39B, up 32% from $1.05B the previous quarter. Its ten largest holdings account for 76% of the portfolio.

RTW Investments deployed $96.4M of net new capital in Q2 2018, opening 8 new positions and adding to 24 existing holdings. Its largest new stake was Qiagen: 499,239 shares worth $19.1M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 94% a quarter earlier.

On the sell side, the largest reduction was Bristol-Myers Squibb, an estimated $10.4M trimmed.

  • RTW Investments's largest Q2 2018 buy was Qiagen: 499,239 shares worth $19.1M.
  • RTW Investments added most to Arrowhead Research in Q2 2018, an estimated $50.3M increase.
  • RTW Investments's biggest Q2 2018 reduction was Bristol-Myers Squibb, cutting an estimated $10.4M.
  • RTW Investments fully exited AveXis, Inc. Common Stock in Q2 2018, selling an estimated $29.2M.
  • RTW Investments's ten largest holdings make up 76% of its $1.39B portfolio in Q2 2018.
  • RTW Investments opened 8 new positions and closed 6 in Q2 2018.
  • RTW Investments's portfolio value rose 32% quarter-over-quarter to $1.39B.

Based on RTW Investments's 13F filing for Q2 2018, filed 14 Aug 2018.